F.-X. Mahon - Concepedia

Author

F.-X. Mahon

Also Known As

F Mahon, F X Mahon, F-X Mahon, F. Mahon, F. X. Mahon, F.-X. Mahon, F.X. Mahon, FranÇOis-Xavier Mahon, François-Xavier Mahon

Publications

Citations

H-Index

Concepts

All Affiliations

Inserm Centre Hospitalier Universitaire de Bordeaux Institut Bergonié Université de Bordeaux Hôpital Cardiologique du Haut-Lévêque

About

F.-X. Mahon is an author at Inserm specializing in oncology, medicine, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	232
2	Health Sciences	1	1	14
3	Allergy	1	1	45
4	Cell Biology	1	1	14
5	Epidemiology	1	1	18

F.-X. Mahon

Publications

545

Citations

H-Index

Page 1

	Year	Citations
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase Francis J. Giles, Hagop M. Kantarjian, Philipp D. le Coutre, Leukemia Hematological MalignancyChronic Myeloid LeukemiaMedicineMixed-phenotype Acute LeukemiaHematology	2011	95
Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa F.-X. Mahon, X. Delbrel, Pascale Cony‐Makhoul, Journal of Clinical Oncology	2002	72
Response at Three Months Is a Good Predictive Factor for Newly Diagnosed Chronic Myeloid Leukemia Patients Treated by Recombinant Interferon- F.-X. Mahon, C. Fabères, Sophie Pueyo, Blood	1998	57
Response at Three Months Is a Good Predictive Factor for Newly Diagnosed Chronic Myeloid Leukemia Patients Treated by Recombinant Interferon- F.-X. Mahon, C. Fabères, Sophie Pueyo, Blood	1998	54
Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy Joerg Hasford, Markus Pfirrmann, Rüdiger Hehlmann, Seminars in Hematology Prognostic FactorsHematological MalignancyChronic Myeloid LeukemiaNontransplant TherapyMedicine	2003	47
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients Alban Bessede, Aurélien Marabelle, Jean‐Philippe Guégan, Annals of Oncology Cancer ImmunosurveillanceAllergyMedicineImmunologyImmune Checkpoint Inhibitor	2022	45
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials Min Tang, Jasmine Foo, M. Gönen, Haematologica	2012	39
Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. F.-X. Mahon, Jean Ripoche, V. Pigeonnier, PubMed	1995	31
Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy Éric Lippert, Gabriel Etienne, Julien Mozziconacci, Haematologica	2010	30
STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF THE EURO-SKI TRIAL Johan Richter, F.-X. Mahon, Joëlle Guilhot, Data Archiving and Networked Services (DANS) Hematological MalignancyLymphoid NeoplasiaHodgkin LymphomaOncologyGeriatrics	2016	18

Page 1